No Data
No Data
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
Breakeven On The Horizon For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) future prospects. Akebia Therapeutics, Inc., a biopharmaceutic
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript